Nuromax

NDA 19946, held by Abbvie. Doxacurium Chloride.

As of Nov 14, 2026, NDA 19946 (Nuromax), held by Abbvie, was first approved by FDA on Mar 7, 1991, with 6 approved supplements and 0 published complete response letters.

First approved: Mar 7, 1991
Review: Standard
Supplements approved: 6
Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 7 submissions below


Dec 8, 1994	Supplement 2Efficacy (new indication or use) · Standard review	Approved	None posted
Mar 7, 1991	Original applicationNew molecular entity · Standard review	Approved	None posted

Products

1 strengths and forms

Product	Active ingredient	Marketing
NuromaxEQ 1MG BASE/ML · injectable;injection	Doxacurium Chloride	Discontinued

All 7 submissions, including labeling and manufacturing supplements


Nov 22, 2010	Supplement 7Labeling · Standard review	Approved	Letter Label
May 30, 2000	Supplement 4Labeling · Standard review	Approved	None posted
May 30, 2000	Supplement 6Labeling · Standard review	Approved	None posted
Dec 5, 1997	Supplement 5Manufacturing · Standard review	Approved	None posted
Dec 8, 1994	Supplement 2Efficacy (new indication or use) · Standard review	Approved	None posted
Jan 24, 1992	Supplement 1Manufacturing · Standard review	Approved	None posted
Mar 7, 1991	Original applicationNew molecular entity · Standard review	Approved	None posted

Identifiers

Application: NDA 19946
Drugs@FDA: Overview at FDA
Company: AbbVie

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters